Kala subsidiary awarded $15M CIRM grant for KPI-012 PCED Phase 2b trial

KALA BIO, Inc.

CIRM awarded Combangio a $15M grant to support KPI-012 for persistent corneal epithelial defect.
Grant funds the CHASE Phase 2b trial, product characterization, and analytical development.
Part of the award is upfront; remainder upon achieving specified milestones.
Combangio must meet a co-funding requirement; Kala committed to provide necessary funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.